Follicular lymphoma in the United States: First report of the national LymphoCare study

Journal of Clinical Oncology

Volumn 27, Issue 8, 2009, Pages 1202-1208

  Link, Brian K ^a   Friedberg, Jonathan W ^b   Taylor, Michael D ^b   Cerhan, James R ^b   Flowers, Christopher R ^b   Dillon, Hildy ^b   Farber, Charles M ^b   Rogers, Eric S ^b   Hainsworth, John D ^b   Wong, Elaine K ^b   Vase, Julie M ^b   Zelenetz, Andrew D ^b  

^a UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUDARABINE; HEMOGLOBIN; LACTATE DEHYDROGENASE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGE; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; DEMOGRAPHY; ETHNICITY; EXTERNAL BEAM RADIOTHERAPY; FEMALE; FOLLICULAR LYMPHOMA; GEOGRAPHIC DISTRIBUTION; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROGNOSIS; STATISTICAL ANALYSIS; TREATMENT OUTCOME; UNITED STATES;

ADULT; AGED; FEMALE; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MIDDLE AGED; NEOPLASM STAGING; SEER PROGRAM;

EID: 62449324950     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.1495     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al: Cancer statistics, 2007. CA Cancer J Clin 57:43-66, 2007
2. Anderson JR, Armitage JO, Weisenburger DD: Epidemiology of the non-Hodgkin's lymphomas: Distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 9:717-720, 1998
3. Swenson WT, Wooldridge JE, Lynch CF, et al: Improved survival of follicular lymphoma patients in the United States. J Clin Oncol 23:5019-5026, 2005
4. Fisher Rl, LeBlanc M, Press OW, et al: New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 23: 8447-8452, 2005
5. Liu Q, Fayad L, Cabanillas F, et al: Improvement of overall and failure-free survival in stage IV follicular lymphoma: 25 years of treatment experience at The University of Texas M. D. Anderson Cancer Center. J Clin Oncol 24:1582-1589, 2006
6. Marcus R, Imrie K, Belch A, et al: CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105:1417-1423, 2005
7. Buske C, Hoster E, Dreyling M, et al: The Follicular Lymphoma International Prognostic Index (FLIPI) separates high-risk from intermediate- or low-risk patients with advanced-stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) with respect to treatment outcome. Blood 108:1504- 1508, 2006
8. Horning SJ, Rosenberg SA: The natural history of initially untreated low-grade non-Hodgkin's lymphomas. N Engl J Med 311:1471- 1475, 1984
9. Rohatiner AZ, Nadler L, Davies AJ, et al: Myeloablative therapy with autologous bone marrow transplantation for follicular lymphoma at the time of second or subsequent remission: Long-term follow-up. J Clin Oncol 25:2554-2559, 2007
10. A predictive model for aggressive non- Hodgkin's lymphoma: The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
11. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 104:1258-1265, 2004
12. Morton LM, Wang SS, Devesa SS, et al: Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265-276, 2006
13. Bastion Y, Coiffier B: Is the International Prognostic Index for aggressive lymphoma patients useful for follicular lymphoma patients? J Clin Oncol 12:1340-1342, 1994
14. Etto LY, Silva VC, Inaoka RJ, et al: Is the follicular lymphoma international prognostic index better than the international prognostic index to identify high-risk follicular lymphoma patients? Leuk Lymphoma 48:526-530, 2007
15. Ganti AK, Weisenburger DD, Smith LM, et al: Patients with grade 3 follicular lymphoma have prolonged relapse-free survival following anthracycline- based chemotherapy: The Nebraska Lymphoma Study Group experience. Ann Oncol 17:920-927, 2006
16. Berrios-Rivera JP, Fang S, Cabanillas ME, et al: Variations in chemotherapy and radiation therapy in a large nationwide and community-based cohort of elderly patients with non-Hodgkin lymphoma. Am J Clin Oncol 30:163-171, 2007
17. Dreyling M, Fetscher S, Kornek P, et al: Treatment of indolent non-Hodgkin's lymphoma in Germany: Results of a representative population- based survey. Blood 110:407a, 2007
18. Montoto S, Lopez-Guillermo A, Ferrer A, et al: Survival after progression in patients with follicular lymphoma: Analysis of prognostic factors. Ann Oncol 13:523-530, 2002
19. Gribben JG: How I treat indolent lymphoma. Blood 109:4617-4626, 2007
20. Montoto S, Davies AJ, Matthews J, et al: Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. J Clin Oncol 25:2426-2433, 2007
21. Ardeshna KM, Smith P, Norton A, et al: Long- term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: A randomised controlled trial. Lancet 362:516-522, 2003
22. Mauch P: Follicular non-Hodgkin's lymphoma: The role of radiation therapy. Ann Hematol 80:B63- B65, 2001 (suppl 3)
23. Tsang RW, Gospodarowicz MK: Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 23:10-17, 2005
24. Guadagnolo BA, Li S, Neuberg D, et al: Long- term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy. Int J Radiat Oncol Biol Phys 64:928-934, 2006
25. Besa PC, McLaughlin PW, Cox JD, et al: Long term assessment of patterns of treatment failure and survival in patients with stage I or II follicular lymphoma. Cancer 75:2361-2367, 1995
26. Zelenetz AD, Advani RH, Buadi F, et al: Non- Hodgkin's lymphoma: Clinical practice guidelines in oncology. J Natl Compr Cane Netw4:258-310, 2006
27. Hiddemann W, Dreyling M, Stahel RA: Minimum clinical recommendations for diagnosis, treatment and follow-up of newly diagnosed follicular lymphoma. Ann Oncol 16:i56-i57, 2005 (suppl 1)
28. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin's lymphoma: Long-term follow-up of no initial therapy. J Clin Oncol 22:1454- 1459, 2004
29. Plancarte F, Lopez-Guillermo A, Arenillas L, et al: Follicular lymphoma in early stages: High risk of relapse and usefulness of the Follicular Lymphoma International Prognostic Index to predict the outcome of patients. Eur J Haematol 76:58- 63, 2006
30. Lara PN Jr, Higdon R, Lim N, et al: Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19:1728-1733, 2001
31. Simon MS, Du W, Flaherty L, et al: Factors associated with breast cancer clinical trials participation and enrollment at a large academic medical center. J Clin Oncol 22:2046-2052, 2004
32. Mannel RS, Walker JL, Gould N, et al: Impact of individual physicians on enrollment of patients into clinical trials. Am J Clin Oncol 26: 171-173, 2003
33. Finn R: Oncologist's role critical to clinical trial enrollment. J Natl Cancer Inst 92:1632-1634, 2000
34. Paskett ED, Cooper MR, Stark N, et al: Clinical trial enrollment of rural patients with cancer. Cancer Pract 10:28-35, 2002
35. Hillner BE: Barriers to clinical trial enrollment: Are state mandates the solution? J Natl Cancer Inst 96:1048-1049, 2004
36. Friedberg JW: Potential long-term toxicities should influence the choice of therapy for indolent non-Hodgkin's lymphoma. Haematologica 91:1453- 1455, 2006
37. Federico M, Bellei M, Marcheselli L, et al: F2 prognostic index. Ann Oncol 19:iv101, 2008 (suppl 4)